{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.19","upperLimit":"0.75","value":"0.41"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"538"}],"units":"Participants"}],"description":"Patient year (PY) refers to duration in study, calculated from first active drug intake to last safety assessment available + 1.\n\nTo calculate the death rate, the total cumulative number of years that all participants were exposed to the drug, from first active drug intake to last safety assessment available + 1, was calculated as 2461.94. Since 10 participants died during that time, the death rate per year was not informative (0.00). Therefore, the overall death rate was calculated with the confidence interval based on events per 100 patient years exposure.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received tocilizumab (TCZ) 8 mg/kg intravenously every 4 weeks.","id":"OG000","title":"Tocilizumab 8 mg/kg"}],"paramType":"NUMBER","populationDescription":"All exposure population, which included all participants who entered the study and received at least one dose of tocilizumab at any time.","reportingStatus":"POSTED","timeFrame":"through 264 Weeks","title":"Overall Death Rate Over Time","type":"PRIMARY","unitOfMeasure":"Deaths per 100 PY"}